# Pharma M&A Hits $123B as the Patent Cliff Bites - The Biotech Patent Cliff & M&A - Week of June 29 to July 3, 2026

> Big Pharma's M&A supercycle hit $123B across 32 billion-dollar deals as ~$300B of revenue rolls off patent, with AbbVie's $10.9B Apogee takeout setting the template and a US-China trials probe landing on Merck and AbbVie. Our synthesis of the biotech M&A podcast tape for the week of June 29 to July 3, 2026.

## The Biotech Patent Cliff & M&A

### Week of June 29 to July 3, 2026: Pharma M&A Hits $123B as the Patent Cliff Bites

---

## TL;DR

- **The buying wave is now a supercycle.** 32 deals of $1B+ worth ~$123B so far in 2026, on pace for the biggest M&A year since 2019, with ~$300B of annual revenue rolling off patent and ~70 blockbusters losing exclusivity in the next couple of years.
- **AbbVie set the template again** with its $10.9B Apogee takeout (49% premium, an immunology bolt-on), while a fresh **US-China trials probe into Merck and AbbVie** and Merck quietly killing a Phase 2 Alzheimer's program are the week's reminders that the buyers have problems of their own.
- **Silence is the tell.** Almost the entire SMID target list, Summit, Madrigal, Viking, Cytokinetics, Insmed, Krystal, Vaxcyte, Roivant, Revolution Medicines, went dark on the tape this week. No new rumors. The cash is real; the named targets aren't moving yet.

## What's new

**1. The M&A tape is running hot, and the numbers are getting silly.** On Motley Fool Hidden Gems' ["Big Pharma Has a Case of Merger Mania" (June 23)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjyURSFmVXNpM6h7YYJpBXB34Q4DoQiWhxGUvL6KsBt0tYWUA5OTYERq5hlD-2FLb1LfPjuvr88NtLwRVappsEK4bVi1xNoPfVaOsk-2FDvTTuGXQ-3D-3DUrhz_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3Opve6fpddswAzFYSIRgSQ6oM76CZvBprI7eLpGrY7bEghypv8jiIyqGGtivgZ3BDhvP9S9LRKBdNPCfAu-2BnLiHGsR8j5aI7U93K-2BTXcusZ7kswyS29wzZyRFwzP0PM0K1jQ-3D-3D), contributor Matt Frankel put hard numbers on the mood: "we've already seen 32 separate deals worth a billion dollars or more for a total deal value of $123 billion... the strongest year for M&A in the space since 2019." His co-host Lou Whiteman framed the *why* in one line: "an estimated $300 billion in annual revenue coming off patent in the next few years," and Frankel added the part PMs should tattoo on their monitors: "Almost 70 drugs that each generate over a billion dollars of revenue have their patents expiring within the next couple of years... it could drop 80 to 90% overnight." Note the structural shift: this is a bolt-on wave, not a mega-merger wave. Merck alone "made three major acquisitions in the last 10 months," all defense against the Keytruda cliff. *This is the whole thesis of this letter, quantified.*

**2. AbbVie bought the wave's marquee asset, and told you why.** Multiple shows dissected the $10.9B Apogee deal, but the cleanest operator quote came on [Citeline's Scrip Five Must-Know Things (June 29)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg2-2Bm11bwc0KU-2F1n-2FVaedNkSThGgC2Mt9cVyQVoaouRrzRc66PwNhmYQXr50V7JqIQhU1TPSH4cjVLhw-2F1I5DFsgc9WK9psVv-2B2FY29-2Fa7Zng-3D-3DYUH6_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OptSFK7zaaVnnrtqvIDa7pBhvOQS-2F4A-2B0NDI466Y8nrlAM7iEpU39pJwBEszjOeDqCwjbF9xsUApoAxeG5LTxjXvE-2FmxrQIhc6W01xosXqgy1-2FEjYSLojXjUp2-2BPcHnppBw-3D-3D): AbbVie CEO **Robert Michael** said the deal brings "multiple differentiated pipeline candidates that should provide mega-blockbuster revenue," aimed at the 2030s. On [Brew Markets (June 22)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgZ-2Ft4RfwD-2Bqz2n9fw-2BbHEUmJ8lfYbhkm5-2F-2BxwwL7lVygaOvi9hbaXeo7iFCC0bmGLpOyzQvXtvhwjLW5fP3J-2F1PwmyhnDn0iI0328wFJczGw-3D-3D10cq_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3Oph8gwlrC86ag8ScNHGT98tqjXdERn-2FzrR6oGmqmSZrjWkzodbKE7PIzOtPq9nqCCqPGG64w-2FxyJJxkmvQKFZdQVflg9Qu3QB4Cxb-2F4-2Bx4SERwBZV8XK-2FtmuKx8MVKrQv8A-3D-3D), John Croteau nailed the terms: "$135 a share in cash, a 49% premium," and the stakes: Skyrizi + Rinvoq immunology "brought in $7.3 billion... nearly half of the company's total revenue," even as Humira has cratered "nearly 40 percent to $688 million" post-2023 LOE. On [BioCentury This Week Ep. 373 (June 23)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjdr3kjf1wC5aeHbajJMDr59j6kWQTbIxYct2u0tMx4-2FSxBmGPTNY0VjsYotuA-2BK4lnvCsIi4kw8vVYaYzqQxyzH4-2B044tMJUsyolRsb2iuhQ-3D-3Dlfow_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3Oppojc6RwvKwNF1obSr-2BWP7ZiO6x4k-2FvI4PK4mXfBMy73BqBoEb-2BhcEBp-2FPaouGlhJJtzJSUHTDD95GYm3OGiPEuTXWpX7ncJ1WaOQQUrx9XKuQI9QACzBMe-2BWh7AT7XlkQ-3D-3D), news editor Paul Bananos flagged the read-through: lead asset Zumilokibat doses "every three months" versus Lilly's Ebglis and Sanofi/Regeneron's Dupixent at "every two to four weeks," and reminded listeners GSK just paid "close to $11 billion for New Valence," its third deal under new CEO Luke Miels. *Two ~$11B immunology bolt-ons in a month tells you where the buyers think the next Humira-sized hole is.*

**3. An operator just described the patent cliff as an M&A engine, from the inside.** On Venrock's [Running Through Walls (June 23)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOissi7CtTciN2JzJO3lRXyF1UmUHMnFeuBC3grAdrVPIS1wadCx-2Fr3BB18xDbmh2eTHyeQpQkHT3QJuHhH2vUpYfYfvUbRQcYyEJEL4SzAG9A-3D-3Dtme2_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OpuXorXV-2BTaZiGNeLiXTvtoRkx9QMLrv-2FgxSDZP31BgTp8ye59e2TQKG8-2Fx9c6-2FHOfZgmmWJ6Y9GUQh95T4sq0VbjYJpUzSfvAmX9JhjRhWNxcrzBc71lAhpYKiz29tETFQ-3D-3D), MetSera CEO **Whit Bernard** walked through how Pfizer won his ultra-long-acting GLP-1 (Meta-097, an "18, 19 day observed half-life" monthly shot), and then, "about a month later," got a topping bid from Novo's CEO by letter, "which... really just doesn't happen in biopharma." His tell on buyer psychology: the asset was valuable because it "address[es] a revenue gap associated with a patent cliff in 2029, 2030... the problem that our colleagues at Pfizer needed to solve strategically." *That's the demand curve for late-stage assets, narrated by the person who sold into it.*

**4. Two fresh overhangs on the biggest buyers.** A bipartisan House China Select Committee opened a national-security probe into whether **Merck and AbbVie** ran clinical trials in China (Xinjiang, military hospitals) that aided the PLA, asking both to respond by July 17 ([Reuters, June 30](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NpeKJbqi1xHn-2BFeix4-2FtwJpp-2FGvnhymKWuIIxgs06DlBARYgE5YpyhZPYT9F6bHSJ0gsICtwsiFaw0xKoVK7uoz1sb5GctZBZDdAcMWrkr3NeVZA1bhzDE25vBB4ab3jQzwb-2BshwP9VjjaF02J0s2r0-3DGxL6_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OpidiAqJhK9mM580xnbVskF7aGLeR00rl1rPTi9zNkXAD2VPLIG8CC9sPBYl5YkQZ4dd3LX8pzBkkT5r0vMKw7mKCaJjs4krLFKcWnh1JAKX5inimu0Zp-2FcJpKIvJT6-2FrIA-3D-3D)). Separately, Merck quietly terminated its Phase 2 Alzheimer's study of MK-1167 for a "business reason" ([ClinicalTrials.gov, July 1](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NsiRk1a5e5laV1UG4DEqKc4BoBDaKrdKabc5aCjdAvRrBS38xNNa-2FrGETIndZHFJWQ-3D-3DBEWR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OptzdgaIQFO5KKA9t4M1OcTxhc28sBhiBBWYsm-2FIHCLbTg40YzS11NQ0LXuHgwKBHkoMiQCG5foTlVZO8sqmGCCstMxEQnWBZ66ljuUXoVZEQn1JFLRpAjK3QWjrkPsuxUg-3D-3D)). This dovetails with a policy angle from the [Scrip (June 29)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg2-2Bm11bwc0KU-2F1n-2FVaedNkSThGgC2Mt9cVyQVoaouRrzRc66PwNhmYQXr50V7JqIQhU1TPSH4cjVLhw-2F1I5DFsgc9WK9psVv-2B2FY29-2Fa7Zng-3D-3DtBrj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OpkOnjQGYMUPvM93gGI4OLav1FIox6rrh0C4gWcHGVMXitwSS9jx6VSO1EcAmLfCQ6vmejlRFE0gcEOwVgPLep4X2l1FzQmzFxjJXs4fWZTxgbWpYM8mLs7qZsMpkDw4qlA-3D-3D) BIO panel: J&J's Leslie Stoltz and Sanofi's Brian Bronk (both operators) warned that proposed US screening of China biopharma deals is *already* killing transactions: Bronk said one deal died "because the potential partner was based in China." *The cheapest late-stage pipelines sit in China; Washington is quietly raising the price of shopping there.*

**5. The GLP-1 kings keep diverging.** On [Wall Street Wildlife E138 (June 28)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhBfyTu3jdIhx-2FswqgEmVRVTOZt-2FrtT-2FaYTzsRTeAxitZSWDlUmbQZ0msYDj7HJoPcDbQqw-2BFe2sJUcPtTlPwJSogGOBbiFbWxCw7u5VDp7aQ-3D-3DXy12_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OpmkXba1n2G2Uu2-2BUtWztRFIh8hs7pVuOOT3rOMO7SrwpraNq6aEZotN7dT-2BLPOeyJvdFVLnPcDOy9Cc8OhJuloQS-2BfSdflOnJO9o21nOm97Bx30W0n-2FU7J09WExwzo03HQ-3D-3D), a Novo shareholder laid out the split with unusual candor: Lilly holds "60-40" of the GLP-1 market; CagriSema "lost" its February head-to-head and "Novo's stock dropped about 15% in a day... $100 billion in market cap" gone. Novo now trades "around 10 times earnings" versus Lilly at "around 40 times," is running "$2.3 billion worth of buybacks," has cut "11% of the global workforce," and is "down like 45% over the last year." Meanwhile [BioCentury Ep. 374 (June 29)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjWD6oxjo4MeQctMPfyA8DVPFap6JEAvSPUa1RIhKNYN-2BgzaUIipR8tlioi2nK-2BNuuJMCpNt9qJEJX3xdpIZB9o7VAfJVLK7vFHJBUtWqAjug-3D-3DfV0B_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OphWPOhWDSPh8Vxy1e8s6mp32xDmy6eox0Ae5BYfzrmfs8N5bjthzRB8Yb6DHKKSpvkzri5j-2BmkwySvoXq0dVV5VJtrFyhp8PEqwtw-2B7EIDdouXy49D-2FwkamwTwRJpuDwug-3D-3D) laid out AstraZeneca's five-program obesity push, including an activin asset (AZD-1043, from the SixPeaks takeout) targeting "10% weight loss as monotherapy." *The obesity duopoly is drawing a determined third entrant with a checkbook.*

## The debate

**The supercycle bull:** The math is unarguable: ~$300B of revenue and ~70 blockbusters go off-patent, and Big Pharma has to buy growth or shrink. A friendlier FDA (post-Prasad rare-disease reversals) has re-rated clinical-stage assets that were "marked down," and Lilly's tirzepatide cash gusher, Evaluate projects it "over 70 billion dollars by 2032, the biggest drug ever," per [Scrip (June 29)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg2-2Bm11bwc0KU-2F1n-2FVaedNkSThGgC2Mt9cVyQVoaouRrzRc66PwNhmYQXr50V7JqIQhU1TPSH4cjVLhw-2F1I5DFsgc9WK9psVv-2B2FY29-2Fa7Zng-3D-3D8QQW_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OppPzipMPAuSODdI-2BKCuPdu5BkmsnKCuzzmA5DfxoF5UUhBgYEPHx5IGZooGYsJ8i-2Fo-2FExO-2BnZmqV7FdKjjSSr0p0Ircx3vvahf1SBKbBjFMKDheIMaDknE5EkQQNEzI7kQ-3D-3D), funds a bottomless bid. Premiums are climbing (STAT's Allison DeAngelis, citing PitchBook, on [Readout Loud 407](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFDQXz2YItfzuVKURplPMJV9qL6u0uAPqB7Nk027j4By0WCJQW-2BbREA5j-2FPEzigaB9s8lZUaAgn5e6fbnnVPl8cQ-3D-3D16To_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OpiDELXU3bZdOS1ufx5V3gJZjQBC-2BAWD-2FIUe1U3ebtXdM4S1ID2f0vyFONYAxd1fA-2FwPM4eDzY5dotx7bMnlq1-2F96T6goDPwgIgXo2sYM6Sxaxh9Aa8BfllCv5bNahDjJiQ-3D-3D), notes the reopened IPO market is pushing sellers to hold out). Own quality SMID assets and collect the takeout premium.

**The cliff-erosion bear:** Bolt-ons don't fix an 80-90% overnight revenue cliff; they paper over it and dilute returns. Over the past decade "only three" of the dozen largest pharmas beat the S&P 500 ([Motley Fool, June 23](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjyURSFmVXNpM6h7YYJpBXB34Q4DoQiWhxGUvL6KsBt0tYWUA5OTYERq5hlD-2FLb1LfPjuvr88NtLwRVappsEK4bVi1xNoPfVaOsk-2FDvTTuGXQ-3D-3DUSTF_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbXuu2ZTcV0u23PttEzYOzXbXdhss0ovn-2FswvuxFWE3OpnxJJ28s11TV9T-2BlifKKyvXh3-2FI0FkuGX8FaXGtICBgvVxC5zoMPe8OJBaItI4bA3y2TL84iZZbfzY5n-2BR0NIYtlDgiWJ4XWwjtPSstuYKJ3-2BR4-2BOgnRa5YwqKHgLdUx7A-3D-3D)): this is a serial value-destroyer of an industry buying at 49% premiums into policy chaos (MFN pricing, a China-deal chill, and now a national-security probe into the two most cliff-exposed buyers). The Novo story is the warning label: cheap can get cheaper when the science slips.

**My take:** Both are right, which is exactly why this is a *stock-picker's* cliff, not a *sector* trade, as Whiteman put it, "I would hate to buy an ETF for this industry." The wave is real and self-reinforcing (sellers now have IPO optionality, so premiums rise), but the buyers' own overhangs mean the safer expression is *owning the targets*, not the acquirers. And the loudest signal this week was the quiet: the named SMID target list didn't move. When the tape is this hot and Summit/Viking/Cytokinetics still aren't generating rumors, the market is telling you the next leg is about *price discovery on premiums*, not a scramble for scarce assets. Stay long optionality, short the idea that any single acquirer is "safe."

## Stocks in play

| Ticker | Bull case | Bear case | Next catalyst / number to watch |
| --- | --- | --- | --- |
| **ABBV** | Serial, disciplined bolt-on machine; Skyrizi/Rinvoq refilled the Humira hole ($7.3B immunology, ~half of revenue) | Paying 49% premiums; Humira still bleeding (−40% to $688M); China-trials probe | Apogee close (Q3 2026); Zumilokibat Phase 3 start "later this year"; House response due July 17 |
| **MRK** | 3 acquisitions in 10 months to out-run the Keytruda cliff; still cash-rich | Keytruda LOE looming; Alzheimer's MK-1167 just axed; China probe | Keytruda subq defense data; next bolt-on; July 17 committee response |
| **LLY** | Tirzepatide toward ">$70B by 2032"; biggest acquirer; funds any bid | 40x earnings leaves no room for error | Retatrutide FDA path; pace of bolt-ons (AbSci, Sangamo assets) |
| **NVO** | ~10x earnings, $2.3B buybacks, restructuring; still #2 in a huge market | Lost the CagriSema head-to-head; −45% in a year; possible value trap | CagriSema diabetes/label data; any pipeline or M&A pivot |
| **PFE** | Won MetSera's monthly GLP-1; "incredibly cheap"; explicit 2029-30 gap to fill | Cliff math is stark; needs deals to work | MetSera (Meta-097) Phase 3 progress; more bolt-ons |
| **AZN** | Five-program obesity push; ~$1.2B spent on a GLP-1/GIP dual; commercial firepower | Late to obesity vs Lilly/Novo depth | Alecoglipron Phase 3 start; AZD-1043 monotherapy weight-loss data |
| **SMMT** | Ivonescimab tops Evaluate's NPV table (">$25B" NPV, "$8.5B" 2032 sales) | No takeout chatter; binary readout risk | Ivonescimab Phase 3 reads; any strategic interest |
| **VRTX** | CASGEVY now approved ages 2+ (SCD/TDT); durable franchise | No M&A/firepower narrative on the tape | CASGEVY pediatric uptake; capital-deployment signals |

## Read-throughs

- **Likely takeout targets:** The tape is loud on *deals done* and silent on *deals next*. With premiums rising on IPO optionality, expect buyers to move faster on de-risked, late-stage, immunology/obesity/oncology assets, the AbbVie/GSK immunology double-tap is the pattern. Watch obesity adjacencies (AZ's build-out validates the category's depth) and RAS/precision-onc names.
- **Biosimilar makers:** Humira's "−40% to $688M" is the live case study in how fast a biologic franchise unwinds once biosimilars land, and J&J's competing *pill* against Skyrizi shows the next erosion vector is oral convenience, not just price. Stelara biosimilar dynamics were quiet this week; that's a gap to fill, not a signal of calm.
- **SMID / XBI sentiment:** A reopened IPO window plus record M&A dollars is a constructive backdrop for small-cap biotech risk appetite, but the lack of named-target rumors argues the beta trade is ahead of the single-name trade.
- **Bankers / CROs:** 32 billion-dollar deals and counting is a banner fee environment; the China-deal chill (per the Sanofi/J&J operators) redirects sourcing toward US/EU assets, which is margin-positive for domestic advisers and pressures China-exposed CRO pipelines.

## What changed vs last week

This is the **inaugural issue**, no prior letter to diff against. Consider this the baseline: the M&A supercycle is confirmed and quantified ($123B / 32 deals), AbbVie is the template setter, Lilly is the balance-sheet whale, Novo is the cautionary tale, and the named SMID target list is, notably, quiet. From here we track deltas: rumors that become deals, deals that close or break, and which of the silent names finally starts generating chatter. Next Friday we'll have something to compare to.